TSXV:NSP.H - Post by User
Post by
Stock20on May 28, 2020 1:16pm
229 Views
Post# 31083496
Soon news about CTA submission to FDA
Soon news about CTA submission to FDA "" The Company is pleased to announce that a Clinical Trial Application (CTA) has been submitted to Health Canada for a COVID-19 Phase 2 clinical trial, using Cavaltinib(TM) as the subject test drug. The same study protocol is being prepared for submission to the U.S. FDA regulatory authorities. ""